top of page

it's where dermatology lives

DERM. CITY 2 copy.png

Search

Jeremy Visser
- Jul 13, 2023
- 1 min read

Long Term Efficacy of Deucravacitinib

Dr. Ronald B. Vender discusses the TYK2 inhibitor deucravacitinib at the World Congress of Dermatology 2023 in Singapore.

Recent Posts

VIDEO: Patients with HS at higher risk of respiratory disease

VIDEO: Depression, suicidal ideation low in PsO patients on bimekizumab, according to new study

VIDEO: New study highlights delays in diagnosis for HS

bottom of page